Argenica Therapeutics Ltd
ASX:AGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Argenica Therapeutics Ltd
Pre-Tax Income
Argenica Therapeutics Ltd
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Argenica Therapeutics Ltd
ASX:AGN
|
Pre-Tax Income
-AU$7.2m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-80%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Pre-Tax Income
-AU$30.3m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Pre-Tax Income
-AU$83.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Pre-Tax Income
AU$38.9m
|
CAGR 3-Years
496%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Pre-Tax Income
-AU$63.9m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Pre-Tax Income
AU$14.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
Argenica Therapeutics Ltd
Glance View
Argenica Therapeutics Ltd. provides neuroprotective treatment. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2021-06-11. Argenica’s lead candidate, ARG-007, aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury. Argenica has accumulated a comprehensive body of published pre-clinical studies demonstrating efficacy of ARG-007 in multiple models of stroke and other central nervous system injury models, including stroke, traumatic brain injury and perinatal hypoxia ischaemia.
See Also
What is Argenica Therapeutics Ltd's Pre-Tax Income?
Pre-Tax Income
-7.2m
AUD
Based on the financial report for Jun 30, 2025, Argenica Therapeutics Ltd's Pre-Tax Income amounts to -7.2m AUD.
What is Argenica Therapeutics Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-80%
Over the last year, the Pre-Tax Income growth was -31%. The average annual Pre-Tax Income growth rates for Argenica Therapeutics Ltd have been -21% over the past three years , -80% over the past five years .
